Interview with Krisja Vermeylen, Vice President Novo Nordisk France &…
Novo Nordisk just celebrated 50 years in France; what have been some of the more recent events that have marked the affiliate’s time here? If you look from the perspective…
Address: Coeur Défense, Tour B 100, Esplanade Charles de Gaulle, 92932 La Défense Cedex
Tel: 01 41 97 66 00
Web: http://www.novonordisk.fr/documents/home_page/document/index.asp
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries.
Haemophilia care, growth hormone therapy and hormone replacement therapy.
Novo Nordisk just celebrated 50 years in France; what have been some of the more recent events that have marked the affiliate’s time here? If you look from the perspective…
The biggest recent stories from French healthcare and the life sciences, including Sanofi’s deal to buy immunology biotech Blueprint; the largest from a European pharma this year. Elsewhere Servier is…
At the end of a turbulent and lengthy process, France’s 2025 health budget has finally been approved. This “imperfect” budget resulting from months of debate in a parliament with no…
A new book by two pharma industry experts offers the first truly global perspective on the complexities of market access. Even the most innovative drug is useless if patients…
François Bayrou’s new administration in France, sworn in after the previous, three-month-old government was toppled by a no-confidence vote, brings a new health minister to a post recently characterized by…
A roundup of the top stories coming out of France’s pharma industry, including Sanofi’s consumer health unit spinout and EUR 40 million investment in antibody bioproduction; the French govenment’s unprecedented…
At the 13th annual meeting of French life sciences think tank, G5 Santé – which represents the leaders of eight major French health and life sciences companies, including bioMérieux, Sanofi,…
In conversation at ESMO 2024, Pierre Fabre’s R&D Head Francesco Hofmann outlines some of the key data readouts for the company’s oncology portfolio from this year’s conference, how it is…
Lionel Collet, president of France’s Haute Autorité de Santé (HAS), explains the role of the independent public authority, which extends beyond health technology assessment (HTA) to clinical practice guidelines and…
FACOPHAR Santé is the French association for actors operating in the natural and herbal remedies field. In conversation with PharmaBoardroom, long-term president Jacques Vernin explains how the organisation promotes French…
The biggest stories from French healthcare and pharma, including AstraZeneca’s acquisition of Amolyt Pharma; protests over Sanofi layoffs; Pierre Fabre’s purchase of Kinnate Biopharma’s experimental pan-RAF inhibitor, and French biotech…
As president of the French League Against Cancer, Dr Daniel Nizri highlights the organization’s 106-year legacy of fighting cancer through research funding, health promotion, patient support, and advocacy. He discusses…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its…
See our Cookie Privacy Policy Here
